Successful tumor necrosis factor α blockade treatment in therapy‐resistant sarcoidosis
- 8 December 2003
- journal article
- case report
- Published by Wiley in Arthritis & Rheumatism
- Vol. 48 (12) , 3542-3543
- https://doi.org/10.1002/art.11357
Abstract
Sarcoidosis is a multisystemic disorder histologically characterized by a noncaseating granulomatous inflammatory process. The etiology remains unclear, but tumor necrosis factor α seems to play a crucial role. Herein we describe a patient with severe sarcoidosis involving the lung and liver. Various treatment regimens with azathioprine, methotrexate, cyclophosphamide, and pentoxifylline failed to control the disease. Therefore, salvage therapy with infliximab was commenced. Arthritis and pulmonary and liver involvement improved. We were then able to taper the corticosteroid treatment to a lower‐dose regimen with no need for additional immunosuppressive treatment. To our knowledge, this is the first reported case of successful treatment of multiorgan sarcoidosis that was previously resistant to conventional therapy.Keywords
This publication has 6 references indexed in Scilit:
- Treatment of Complicated Sarcoidosis with Infliximab Anti–Tumor Necrosis Factor-α TherapyAnnals of Internal Medicine, 2001
- Effects of Tumor Necrosis Factor Alpha on Host Immune Response in Chronic Persistent Tuberculosis: Possible Role for Limiting PathologyInfection and Immunity, 2001
- Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritisArthritis & Rheumatism, 1998
- TUMOUR NECROSIS FACTOR ALPHA PROMOTER GENE POLYMORPHISM IN SARCOIDOSISCytokine, 1997
- Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritisThe Lancet, 1994